Hypoxia-inducing factor (HIF)-1 α-derived peptide capable of inducing cancer-reactive cytotoxic T lymphocytes from HLA-A24(+) patients with renal cell carcinoma.

In this study, we searched for HIF-1α-derived peptides that are able to induce RCC-reactive cytotoxic T lymphocytes (CTLs) from HLA-A24(+) RCC patients. Among five peptides derived from HIF-1α, which were prepared based on the binding motif to the HLA-A24 allele, a HIF-1α278-287 peptide induced peptide-specific CTLs from peripheral blood mononuclear cells of HLA-A24(+) RCC patients most effectively. In immunoblot assays, the expression of HIF-1α was lowly detected in whole and nuclear lysates of RCC cell lines even under normoxia (20% O2), and their expression in whole lysates was increased under hypoxia (1% O2). Additionally, HIF-1α278-287 peptide-stimulated T cells showed a higher cytotoxicity against HLA-A24(+) HIF-1α-expressing RCC cells than against HLA-A24(-) HIF-1α-expressing RCC cells. The cytotoxicity was inhibited by the addition of HIF-1α278-287 peptide-pulsed cold target cells. Altogether, these results indicate that the HIF-1α278-287 peptide could be a candidate for peptide-based anti-cancer vaccines for HLA-A24(+) RCC patients.
PMID: 28110220 [PubMed - as supplied by publisher]

Source: International Immunopharmacology - January 18, 2017 Category: Allergy & Immunology Authors: Minami T, Matsumura N, Sugimoto K, Shimizu N, De Velasco M, Nozawa M, Yoshimura K, Harashima N, Harada M, Uemura H Tags: Int Immunopharmacol Source Type: research